Searchable abstracts of presentations at key conferences in endocrinology

ea0081p667 | Pituitary and Neuroendocrinology | ECE2022

Pituitary adenoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: a single-center study

Modica Roberta , Liccardi Alessia , Minotta Roberto , Cannavale Giuseppe , Benevento Elio , Colao Annamaria

Background: Multiple endocrine neoplasia type 1 (MEN1), is an autosomal dominant inherited disorder with high penentrance, characterized by the onset of multiple tumors, mainly in parathyroid, pituitary gland and gastroenteropancreatic tract. During the course of the disease pituitary adenomas (PA) occur in 20-65%, rarely as first clinical manifestation, and are often described as larger, more aggressive, and more resistant to conventional therapy than their sporadic counterpa...

ea0090p695 | Pituitary and Neuroendocrinology | ECE2023

Sporadic neuroendocrine neoplasm: a survival analysis in a monocentric cohort

Liccardi Alessia , Minotta Roberto , Cannavale Giuseppe , Benevento Elio , Modica Roberta , Colao Annamaria

Introduction: Neuroendocrine neoplasms (NEN) are heterogeneous tumors, usually sporadic and non-functioning, with a favorable long-term prognosis if localized. Metastases are common and survival outcomes of metastatic patients (pts) is worse than in localized disease.Aim: To investigate survival outcomes in a monocentric cohort of sporadic NEN.Materials and Methods: Clinical data of pts with histologically confirmed sporadic NEN, r...

ea0070aep622 | Pituitary and Neuroendocrinology | ECE2020

Sporadic neuroendocrine neoplasms in young-adult patients: Differences in natural history, prognosis and treatment compared to adult-elderly patients

Altieri Barbara , Modica Roberta , Bottiglieri Filomena , de Cicco Federica , Faggiano Antongiulio , Colao Annamaria

Introduction: Sporadic neuroendocrine neoplasms (NEN) occur rarely in young-adult (YA) patients, with an estimated incidence is about 2.8 cases per million, and data specific to their epidemiology are limited. The aim of our study was to better characterize the natural history, prognosis and management of NEN in YA patients (≤ 35 years old) compared to adult-elderly (AE; >35 years old).Methods: A retrospective observational study including 204 ...

ea0070ep484 | Thyroid | ECE2020

Clinical presentation and prognosis of patients with medullary thyroid cancer

de Cicco Federica , Modica Roberta , Barba Livia , Bottiglieri Filomena , Minotta Roberto , Faggiano Antongiulio , Colao Annamaria

Medullary thyroid carcinoma (MTC) is a rare type of tumor that originates from parafollicular C-cells and accounts for 3–4% of all malignant thyroid neoplasms. MTC presents as sporadic (75–80%) or inherited tumors (20–25%). Hereditary MTC is part of multiple endocrine neoplasia type 2 (MEN2). Aim of the study was to describe clinical presentation, prognosis and therapy of sporadic MTC patients. Sixty-seven patients (pts) with histologically confirmed MTC refe...

ea0056p135 | Endocrine tumours and neoplasia | ECE2018

Multiple endocrine neoplasia type 1: a retrospective monocenter analysis of 73 cases

Modica Roberta , Lo Calzo Fabio , de Cicco Federica , Bottiglieri Filomena , Sciammarella Concetta , Colao Annamaria , Faggiano Antongiulio

Multiple endocrine neoplasia type 1 (MEN1) is an inherited syndrome, affecting multiple endocrine glands whose natural history remains largely unknown. Aim of this study was to assess the epidemiological and clinical profile of MEN1 in a single center. Seventy-three MEN1 patients, belonging to 30 different families, referred at the NET Center of Naples, from 2000 to 2017, were evaluated. Male/female ratio was 0.73, mean age 43 years (range 10–86). Forty-six cases (64%) we...

ea0063p440 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Neuroendocrine neoplasms (NEN) arising in uncommon sites: epidemiological and clinical features

Modica Roberta , de Cicco Federica , Bottiglieri Filomena , Di Maio Silvana , Altieri Barbara , Rainone Carmen , Faggiano Antongiulio , Colao Annamaria

Background and aim: Neuroendocrine neoplasms (NEN) show increasing incidence and varying biology, but epidemiological and clinical data for other than gastroenteropancreatic (GEP) and thoracic NEN are scattered. Furthermore the best therapeutic approach in NEN arising in uncommon sites is still debated. Aim of this study is to assess the epidemiological and clinical features of NEN arising in uncommon sites in a monocentric series of a referral center.Ma...

ea0070aep718 | Pituitary and Neuroendocrinology | ECE2020

Evaluation of early predictors of metabolic syndrome in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET)

Bottiglieri Filomena , Modica Roberta , Barrea Luigi , de Cicco Federica , Minotta Roberto , Muscogiuri Giovanna , Savastano Silvia , Faggiano Antongiulio , Colao Annamaria

Metabolic syndrome and obesity (MetS) are supposed to have a role in cancer but data analysing their association with GEP-NET are lacking. Aim of this study was to explore the association of early predictors of MetS with GEP-NET, usingas tools Fatty Liver Index (FLI), a predictor of non-alcoholic fatty liver disease (NAFLD)and Visceral Adiposity Index (VAI), a gender-specific indicator of adipose dysfunction. A cross-sectional case-control observational study was conducted. VA...

ea0063gp2 | Adrenal and Neuroendocrine - Tumour | ECE2019

Lanreotide therapy vs wait-and-see in patients with pancreatic neuroendocrine tumors

Faggiano Antongiulio , Modica Roberta , Calzo Fabio Lo , Camera Luigi , Napolitano Vincenzo , Altieri Barbara , De Cicco Federica , Bottiglieri Filomena , Sesti Franz , Isidori Andrea M. , Colao Annamaria

Background & Aim: Pancreatic neuroendocrine tumors (pNETs) are detected in >80% of MEN1 patients. MEN1 pNETs are well differentiated G1-G2 NETs. They are usually not surged unless a size >1–2 cm or a growth rate >0.5 cm per year. Somatostatin analogues represent one of the main therapeutic option in patients affected with G1-G2 NETs. However, neither somatostatin analogues nor other therapies have been prospectively evaluated in clinical trials specificall...

ea0063p36 | Adrenal and Neuroendocrine Tumours 1 | ECE2019

Vitamin D deficiency is a predictor marker of tumor aggressiveness in sporadic and MEN1-related well-differentiated, low-grade GEP-NET

Altieri Barbara , Barrea Luigi , Modica Roberta , Circelli Luisa , Bottiglieri Filomena , Cicco Federica De , Savarese Giovanni , Somma Carolina Di , Colao Annamaria , Savastano Silvia , Faggiano Antongiulio

Background: Vitamin D has several ‘noncalcemic’ implications, including effects on cell signaling and differentiation. Patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NET) have an increased risk of vitamin D deficiency, due to the tumor itself, systemic therapies and abdominal surgery. However, data regarding vitamin D status are limited. Aim of this study was to evaluate 25-hydroxy-vitamin-D (25(OH)D) levels in GEP-NET patients and correlated them ...

ea0037ep1132 | Endocrine tumours | ECE2015

High-dose treatment with somatostatin analogues in neuroendocrine tumours

Modica Roberta , Ramundo Valeria , Marciello Francesca , Marotta Vincenzo , Pizza Genoveffa , Carratu Anna Chiara , Roseto Chiara de Luca di , Buonomano Pasqualina , Giordano Carla , Trimarchi Francesco , Colao Annamaria , Faggiano Antongiulio

Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical. Aim of this study is to evaluate efficacy and safety of high-dose SSA treatment in patients with progressive disease under standard SSA dose. Twenty-one patients (median age 56.8 years) with NET of different orig...